Monitoring direct oral anticoagulants

Our software is designed to make sure that patients on the direct oral anticoagulants (DOACs) can be regularly reviewed and followed up as part of a normal anticoagulation clinic.

INRstar supports the following vitamin K antagonists:

  • warfarin (Coumadin)
  • acenocoumarol (Sinthrome)

INRstar supports the following low molecular weight heparins:

  • enoxaparin (Clexane)
  • dalteparin (Fragmin)

INRstar supports the following DOACs

  • apixaban (Eliquis)
  • dabigatran (Pradaxa)
  • rivaroxaban (Xarelto)
  • edoxaban (Lixiana)

All your anticoagulation patients in one place

Now you can manage all your anticoagulation patients in one central place, including patients on DOACs.

Monitoring your DOAC patients in INRstar ensures that all patients are reviewed at the right time as part of your usual anticoagulation clinic and allows for effective cross reporting across all anticoagulation patients.

“Reviewing and monitoring our patients is absolutely vital to our service and we are keen to have a means of reviewing patients on different medications in one place.”
Sherra Aynin, Anticoagulation Sister, St. George’s Hospital, London.

The importance of regular reviews for patients on a DOAC

Although patients taking a DOAC do not need regular INR tests, the national experts still recommend regular clinical review.1 Many anticoagulation services are now adapting their clinics to cater for patients taking the newer agents in light of this advice.

1 “After patients start on a NOAC, it is good practice for clinicians to see them for regular review, preferably every three months” – NICE Implementation Collaborative (NIC) Consensus Statement on the Use of NOACs, June 2014.

Dr Matthew Fay FRCP (Edin.), GP Principal, Westcliffe Medical Practice comments:

“Patients receiving non-vitamin K oral anticoagulants (DOACs) should be kept under ongoing surveillance. The frequency of this review should be determined by their personal characteristics and co-morbidities, although should be no less than 2 times per year.”


How does it work?

The home page messages proactively alert you to DOAC patients who are overdue a review, ensuring no patients are lost to follow up.

INRstar allows you to set up DOAC treatment plans and schedule regular reviews to:

  • Track compliance
  • Record relevant blood results
  • Calculate creatinine clearance
  • Monitor adverse events
  • Record dosing information
  • Record risk assessment CHA2DS2 VASc and HAS-BLED score

Using INRstar to manage your DOAC patients enables you to:

  • Improve compliance and patient safety
  • Ensure patients are followed up when necessary
  • Record DOAC patients initiations and follow ups

“I was really pleased that INRstar had the required functionality to manage direct oral anticoagulants (DOACs), which our previous system was unable to do. With INRstar N3 I am now able to run the correct audit on DOACs, which are requested by interval. With the introduction of DOACs, it is vital that patients are monitored when they switch to the new medication, and INRstar gives me the confidence that I am doing just that.”
Vanessa Andreae, Practice Nurse at Bush Doctors in Shepherds Bush, London

Discover how our customers are using INRstar to support DOAC patients

[DOAC] Patients should return on a regular basis for on-going review of their treatment, preferably every 3 months. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation.